GlaxoSmithKline plc (GSK)

Migration, Crosslink

📖

GlaxoSmithKline plc (GSK)

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-glaxosmithkline

📖 Wiki Page

company853 wordssynced 2026-04-02

Overview

flowchart TD companies_glaxosmithkline["GlaxoSmithKline plc GSK"] style companies_glaxosmithkline fill:#4fc3f7,stroke:#333,color:#000 companies_glaxosmith_0["Company Information"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_0 style companies_glaxosmith_0 fill:#81c784,stroke:#333,color:#000 companies_glaxosmith_1["Business Structure"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_1 style companies_glaxosmith_1 fill:#ef5350,stroke:#333,color:#000 companies_glaxosmith_2["Corporate Overview"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_2 style companies_glaxosmith_2 fill:#ffd54f,stroke:#333,color:#000 companies_glaxosmith_3["Research and Development"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_3 style companies_glaxosmith_3 fill:#ce93d8,stroke:#333,color:#000 companies_glaxosmith_4["Neuroscience Pipeline"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_4 style companies_glaxosmith_4 fill:#4fc3f7,stroke:#333,color:#000 companies_glaxosmith_5["Alzheimers Disease Programs"] companies_glaxosmithkline -->|"includes"| companies_glaxosmith_5 style companies_glaxosmith_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

GlaxoSmithKline (GSK) is a British multinational pharmaceutical company headquartered in London, with operations in over 100 countries. The company has maintained a strategic interest in neuroscience, with particular focus on neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.[@glaxosmithkline][@gsk2024]

Business Structure

Corporate Overview

GSK operates as one of the world's largest pharmaceutical companies with three main business divisions:

Vaccines: Leading vaccine developer and manufacturer

Specialty Medicines: Oncology, immunology, and rare diseases

General Medicines: Broad portfolio of established medicines

Neuroscience research falls primarily within the Specialty Medicines division.

Research and Development

GSK maintains significant R&D operations:

Global R&D centers in UK, US, and Belgium
Focus on human genetics and immunology
Emphasis on targeted therapies and biomarkers

Neuroscience Pipeline

Alzheimer's Disease Programs

| Program | Target | Mechanism | Stage |
|---------|--------|-----------|-------|
| Tau programs | Tau protein | Various approaches | Discovery |
| OT-805 | Tau | Antibody | Preclinical |
| AL101 collaboration | Progranulin | Antibody | Phase 2 (with Alector) |
| Neuroinflammation | TREM2, IL-34/CSF-1R | Immunomodulation | Research |
| [Gamma-secretase](/entities/gamma-secretase) | [APP](/entities/app-protein) processing | Modulator | Previous trials |

Parkinson's Disease Programs

| Program | Target | Mechanism | Stage |
|---------|--------|-----------|-------|
| [LRRK2](/entities/lrrk2) programs | LRRK2 kinase | Kinase inhibitors | Discovery |
| [GBA](/entities/gba) programs | Glucocerebrosidase | Chaperones | Preclinical (with Gain) |
| Alpha-synuclein | α-Syn | Various approaches | Research |
| Mitochondrial targets | Mitochondrial dysfunction | Neuroprotection | Research |

Other CNS Programs

GSK maintains research programs in:

Multiple CNS disorders
Neuropsychiatric conditions
Pain and sensory disorders
Rare neurological diseases

Technology Platform

GSK's neuroscience research leverages:

Genomics and genetics: Target discovery through human genetics
Immunology expertise: Neuroinflammation modulation approaches
Gene therapy: Exploring gene therapy for neurological disorders[@gsk]
Small molecule platform: Kinase inhibitors for CNS targets

Key Research Capabilities

Human Genetics: Leveraging UK Biobank and genetic databases

Immunology: Applying immunological expertise to neuroinflammation

RNAi/siRNA: RNA interference technologies

AAV vectors: Adeno-associated virus for gene delivery

Drug Discovery Approach

GSK employs multiple modalities:

Small molecule inhibitors
Monoclonal antibodies
Gene therapy vectors
RNA-based therapeutics

Research Focus

Alzheimer's Disease Research

GSK's Alzheimer's research includes:

Tau-targeting therapeutics: Including OT-805 in partnership
Amyloid research: Through partnerships with biotech companies
Neuroinflammation modulation: TREM2, IL-34/CSF-1R pathways
Synaptic plasticity: Memory restoration approaches
Genetic risk factors: [APOE](/proteins/apoe), TREM2, and other GWAS hits

Parkinson's Disease Research

Parkinson's programs focus on:

LRRK2 inhibitor research: GSK'257 and related compounds
Alpha-synuclein targeting: Multiple modalities
Neuroprotective strategies: Disease modification
Mitochondrial dysfunction pathways: Targeting energy metabolism
GBA-related PD: Collaborations with Gain Therapeutics

Strategic Partnerships

Biotechnology Collaborations

Alector: AL101 (progranulin antibody) — 50-50 US profit share, tiered royalties ex-US
Gain Therapeutics: GCase modulators for PD
Tau-targeting biotech: Various collaborations on tau programs
Gene therapy companies: AAV delivery partnerships

Academic Partnerships

Oxford University: Neuroscience research collaboration
Cambridge University: Neurodegeneration research
UK Dementia Research Institute: Dementia research initiatives

Consortium Involvement

Parkinson's Progression Markers Initiative (PPMI): Disease progression research
CRANBERRY Project: EU-funded neurodegeneration biomarker research[@cranberry]
Michael J. Fox Foundation: LRRK2 genetics collaboration

Clinical Trial History

Alzheimer's Disease Trials

GSK has conducted multiple AD trials:

Gamma-secretase modulator trials (completed)
Multiple Phase 1/2 studies
Current Phase 2 trials with Alector

Parkinson's Disease Trials

LRRK2 inhibitor studies
Neuroprotective agent trials
Combination therapy trials

Key Leadership

Emma Walmsley (CEO) — Leading company's strategic direction
Dr. Tony Wood (Chief Scientific Officer)
Dr. John Kemp (Former Head of Neuroscience Research)

Financial Overview

| Metric | Value |
|--------|-------|
| Market Cap | ~$85 billion |
| Annual Revenue | ~£30 billion |
| R&D Investment | ~£5 billion/year |
| Neuroscience (est.) | 5-8% of R&D |

Relevance to Neurodegeneration

GSK's neuroscience programs address key mechanisms in neurodegenerative diseases:

[Tau](/proteins/tau) — Neurofibrillary tangles and disease progression
[LRRK2](/genes/lrrk2) — Parkinson's disease kinase
[Alpha-synuclein](/proteins/alpha-synuclein) — Lewy body pathology
[TREM2](/proteins/trem2) — Microglial activation and neuroinflammation
[Neuroinflammation](/mechanisms/neuroinflammation) — Glial activation
[GBA1](/genes/gba1) — Glucocerebrosidase and PD risk
[Progranulin](/proteins/progranulin-protein) — Frontotemporal dementia

Cross-References

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Tau Protein](/proteins/tau)
[LRRK2](/genes/lrrk2)
[TREM2](/proteins/trem2)
[Alpha-synuclein](/proteins/alpha-synuclein)
[Progranulin](/proteins/progranulin-protein)
[Alector](/companies/alector)
[Gain Therapeutics](/companies/gain-therapeutics)

External Links

[GSK Official Website](https://www.gsk.com/)
[GSK Research](https://www.gsk.com/en-us/research/)
[GSK Annual Report 2024](https://www.gsk.com/en-us/investors/annual-report/)
[GSK Pipeline](https://www.gsk.com/en-us/research/pipeline/)
[ClinicalTrials.gov](https://clinicaltrials.gov)

References

Unknown, GlaxoSmithKline - Wikipedia (n.d.)

Unknown, GSK Annual Report 2024 (2024)

Unknown, GSK Neuroscience Research (n.d.)

Unknown, CRANBERRY Project - EU Neurodegeneration Research (n.d.)

[Kemp J, et al., LRRK2 Kinase Inhibitors: From Discovery to Clinical Development. J Parkinsons Dis. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33877204/)

📖 View canonical wiki page →

Related Entities

companies-glaxosmithkline

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-glaxosmithkline
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1d2ca03ced13
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-glaxosmithkline'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GlaxoSmithKline plc (GSK)

Overview

Overview

Company Information

Business Structure

Corporate Overview

Research and Development

Neuroscience Pipeline

Alzheimer's Disease Programs

Parkinson's Disease Programs

Other CNS Programs

Technology Platform

GSK's neuroscience research leverages:

Key Research Capabilities

Drug Discovery Approach

Research Focus

Alzheimer's Disease Research

Parkinson's Disease Research

Strategic Partnerships

Biotechnology Collaborations

Academic Partnerships

Consortium Involvement

Clinical Trial History

Alzheimer's Disease Trials

Parkinson's Disease Trials

Key Leadership

Financial Overview

Relevance to Neurodegeneration

Cross-References

External Links

References

💬 Discussion